- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Patent holdings for IPC class A61K 31/535
Total number of patents in this class: 1153
10-year publication summary
|
55
|
46
|
32
|
35
|
19
|
19
|
20
|
16
|
20
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline LLC | 533 |
29 |
| Merck Sharp & Dohme Corp. | 2185 |
22 |
| Merck Sharp & Dohme LLC | 3726 |
22 |
| Novartis AG | 10450 |
20 |
| Bristol-myers Squibb Company | 4824 |
20 |
| Boehringer Ingelheim International GmbH | 4569 |
19 |
| Janssen Pharmaceutica N.V. | 3267 |
19 |
| F. Hoffmann-La Roche AG | 7861 |
17 |
| Allergan, Inc. | 2245 |
15 |
| Curis, Inc. | 130 |
15 |
| Shionogi & Co., Ltd. | 834 |
13 |
| Genentech, Inc. | 4063 |
12 |
| The Regents of the University of California | 20494 |
11 |
| Gilead Sciences, Inc. | 2167 |
11 |
| The Trustees of Columbia University in the City of New York | 3621 |
10 |
| Rigel Pharmaceuticals, Inc. | 513 |
10 |
| Glaxo Group Limited | 4293 |
9 |
| Agios Pharmaceuticals, Inc | 220 |
9 |
| Merck Patent GmbH | 5733 |
8 |
| Vitae Pharmaceuticals, Inc. | 94 |
8 |
| Other owners | 854 |